Novartis Q1 results
This article was originally published in The Tan Sheet
Strong first-quarter sales of cough/cold products including Theraflu were "partially offset by a shrinking smoking-cessation market in Europe," Novartis said in an April 21 release. The firm's net consumer sales rose 9% to $1.7 bil. due in part to double-digit growth in the medical nutrition and OTC drug businesses; increased volumes accounted for 5% of the growth, currency exchange for 3% and acquisitions for 1%. Novartis' overall sales advanced 11% to $7.3 bil. with net earnings up 16% to $1.4 bil...
You may also be interested in...
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?
Coronavirus Update: Moderna’s Variant-Targeting Vaccine Moves Into Trial, J&J Looks Set For US Authorization
A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.